What is CytoSeek?
CytoSeek operates at the intersection of advanced biotechnology and precision medicine, specializing in the development of sophisticated targeting technologies for lipid nanoparticles. By utilizing its proprietary NanoPilot platform, the company addresses the fundamental challenge of drug delivery: achieving high-precision therapeutic impact while mitigating off-target toxicity. This capability is essential for expanding the reach of modern medicine, particularly in the realms of cell and gene therapy, oncology, and infectious disease vaccines. As a Bristol-based innovator, CytoSeek is effectively bridging the gap between laboratory-scale research and clinical-grade application, positioning itself as a key enabler for next-generation pharmaceutical modalities.
How much funding has CytoSeek raised?
CytoSeek has raised a total of $5.6M across 2 funding rounds:
Angel/Seed
$774K
Private Equity
$4.9M
Angel/Seed (2019): $774K, investors not publicly disclosed
Private Equity (2021): $4.9M led by Science Creates Ventures
Key Investors in CytoSeek
Science Creates Ventures
A venture capital firm specializing in deep-tech and science-led startups, focusing on commercializing research from academic institutions.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for CytoSeek?
With the recent infusion of capital, CytoSeek is poised to scale its operational infrastructure and expand its clinical trial capabilities. The strategic focus will likely shift toward optimizing the NanoPilot platform for broader therapeutic applications, including complex autoimmune conditions and advanced cancer vaccines. By prioritizing the scalability of its LNP targeting solutions, the company aims to establish long-term partnerships with global pharmaceutical entities, thereby cementing its role as a foundational technology provider in the global biotech ecosystem. Future growth will be defined by the successful transition of its pipeline assets into human clinical trials, a move that will validate the commercial viability of its precision delivery model.
See full CytoSeek company page
